Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DYN

Dyne Therapeutics Inc

Feb 13 • 04:00PM ET

15.54

-0.46 -2.88 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF VBR IBB VTWO IWN SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.66	Insider Own	26.51%	Shs Outstand	142.61M	Perf Week	-7.50%
Market Cap	2.51B	Forward P/E	-	EPS next Y	-3.25	Insider Trans	-0.03%	Shs Float	118.92M	Perf Month	-10.95%
Enterprise Value	1.84B	PEG	-	EPS next Q	-0.76	Inst Own	87.99%	Short Float	16.14%	Perf Quarter	-16.50%
Income	-423.80M	P/S	-	EPS this Y	-3.91%	Inst Trans	51.09%	Short Ratio	7.70	Perf Half Y	24.32%
Sales	0.00M	P/B	3.20	EPS next Y	7.20%	ROA	-51.81%	Short Interest	19.19M	Perf YTD	-20.55%
Book/sh	4.85	P/C	3.18	EPS next 5Y	4.87%	ROE	-60.66%	52W High	25.00 -37.84%	Perf Year	10.60%
Cash/sh	4.89	P/FCF	-	EPS past 3/5Y	-4.75% -59.45%	ROIC	-52.50%	52W Low	6.36 144.34%	Perf 3Y	16.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.57% 5.92%	Perf 5Y	-16.50%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-2.75%	Oper. Margin	-	ATR (14)	1.04	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.47	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.23	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	13.47	EPS Q/Q	20.87%	SMA20	-10.70%	Beta	1.34	Target Price	39.12
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	-15.82%	Rel Volume	0.36	Prev Close	16.00
Employees	191	LT Debt/Eq	0.17	Earnings	Nov 05 AMC	SMA200	4.58%	Avg Volume	2.49M	Price	15.54
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.21% -	Trades		Volume	898,857	Change	-2.88%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Feb-16-26 12:23PM	Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry (Insider Monkey)
Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
07:30AM	Loading…
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Loading…
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Loading…
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)
06:30AM	Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts (GlobeNewswire)
Aug-29-24 07:30AM	Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-24 10:52PM	DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024 (InvestorPlace)
05:10PM	Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-29-24 08:50AM	Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why (Zacks)
Jul-18-24 12:00PM	What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now? (Zacks)
Jul-12-24 08:50AM	Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jun-24-24 07:30AM	Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease (GlobeNewswire)

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 13 '25	Sale	12.12	143	1,733	96,057	Mar 13 04:13 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 11 '25	Sale	11.38	1,343	15,283	122,330	Mar 13 04:08 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 11 '25	Sale	11.38	2,153	24,501	195,840	Mar 13 04:08 PM
Beskrovnaya Oxana	Officer	Mar 11 '25	Proposed Sale	11.38	2,153	24,493		Mar 11 04:09 PM
Scalzo Richard William	Officer	Mar 11 '25	Proposed Sale	11.38	1,343	15,278		Mar 11 04:08 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '25	Sale	11.83	1,343	15,888	94,157	Mar 07 04:08 PM
Cox John	CEO & President	Mar 05 '25	Sale	11.83	4,061	48,042	146,239	Mar 07 04:07 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Mar 05 '25	Sale	11.83	917	10,848	123,673	Mar 07 04:06 PM
Beskrovnaya Oxana	Chief Scientific Officer	Mar 05 '25	Sale	11.83	1,094	12,942	197,993	Mar 07 04:04 PM
Kerr Douglas	Officer	Mar 05 '25	Proposed Sale	11.89	1,343	15,968		Mar 05 04:10 PM
Cox John	Officer	Mar 05 '25	Proposed Sale	11.89	4,067	48,356		Mar 05 04:09 PM
Beskrovnaya Oxana	Officer	Mar 05 '25	Proposed Sale	11.89	1,094	13,007		Mar 05 04:08 PM
Scalzo Richard William	Officer	Mar 05 '25	Proposed Sale	11.89	915	10,879		Mar 05 04:07 PM
Beskrovnaya Oxana	Chief Scientific Officer	Feb 18 '25	Sale	13.95	2,598	36,242	199,087	Feb 25 05:09 PM
Scalzo Richard William	SVP, Head of Finance & Admin.	Feb 18 '25	Sale	13.95	2,488	34,708	124,590	Feb 18 05:09 PM
Scalzo Richard William	Officer	Feb 18 '25	Proposed Sale	13.91	2,488	34,608		Feb 18 04:15 PM
Beskrovnaya Oxana	Officer	Feb 18 '25	Proposed Sale	13.91	2,598	36,138		Feb 18 04:14 PM

Open in Screener

SGMO

Sangamo Therapeutics Inc

Feb 13 • 04:00PM ET

0.3869

+0.0081 2.14 %

Healthcare • Biotechnology • USA • NASD

SGMO Sangamo Therapeutics Inc daily Stock Chart

Peers: GILD CRSP NTLA BMRN EDIT QURE BLUE KYNB VYGR VXRT

| Held by: VTI VXF SCHA PRFZ ITOT SCHB GNOM QQQS XDNA BTEC

Index	-	P/E	-	EPS (ttm)	-0.44	Insider Own	2.15%	Shs Outstand	336.49M	Perf Week	-3.28%
Market Cap	143.80M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	329.25M	Perf Month	-10.65%
Enterprise Value	138.69M	PEG	-	EPS next Q	0.01	Inst Own	17.53%	Short Float	7.48%	Perf Quarter	-17.68%
Income	-108.91M	P/S	4.37	EPS this Y	36.89%	Inst Trans	1.64%	Short Ratio	3.43	Perf Half Y	-28.35%
Sales	32.88M	P/B	19.95	EPS next Y	21.03%	ROA	-108.96%	Short Interest	24.62M	Perf YTD	-7.88%
Book/sh	0.02	P/C	4.71	EPS next 5Y	73.79%	ROE	-480.02%	52W High	1.24 -68.76%	Perf Year	-66.93%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	26.70% 10.57%	ROIC	-343.92%	52W Low	0.34 12.14%	Perf 3Y	-87.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.48% -10.81%	Gross Margin	76.11%	Volatility	7.25% 11.43%	Perf 5Y	-97.17%
Dividend TTM	-	EV/Sales	4.22	EPS Y/Y TTM	40.47%	Oper. Margin	-335.55%	ATR (14)	0.05	Perf 10Y	-92.20%
Dividend Ex-Date	-	Quick Ratio	0.88	Sales Y/Y TTM	-37.13%	Profit Margin	-331.28%	RSI (14)	45.89	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.88	EPS Q/Q	-362.10%	SMA20	-4.71%	Beta	1.37	Target Price	3.81
Payout	-	Debt/Eq	4.07	Sales Q/Q	-98.82%	SMA50	-10.82%	Rel Volume	0.35	Prev Close	0.38
Employees	183	LT Debt/Eq	4.07	Earnings	Nov 06 BMO	SMA200	-25.32%	Avg Volume	7.18M	Price	0.39
IPO	Apr 06, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21900.00% -98.31%	Trades		Volume	2,541,865	Change	2.14%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-25	Downgrade	Barclays	Overweight → Equal Weight	$1
Dec-13-24	Upgrade	Truist	Hold → Buy	$7
Dec-10-24	Reiterated	H.C. Wainwright	Buy	$10
Nov-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$6 → $2
Apr-28-23	Downgrade	BofA Securities	Neutral → Underperform	$5 → $1.50
Feb-27-23	Upgrade	Wedbush	Neutral → Outperform	$16
Jan-06-23	Downgrade	BofA Securities	Buy → Neutral	$8 → $5
Jun-13-22	Resumed	Wedbush	Neutral	$5
May-04-21	Initiated	RBC Capital Mkts	Outperform	$22
Jan-07-21	Resumed	Guggenheim	Neutral	$16
Jan-06-21	Initiated	Stifel	Hold	$16
Dec-16-20	Resumed	H.C. Wainwright	Buy	$25
Sep-08-20	Initiated	BofA Securities	Buy	$20
Jul-07-20	Initiated	SunTrust	Buy	$22
Aug-26-19	Initiated	H.C. Wainwright	Buy	$16
Nov-14-18	Downgrade	JP Morgan	Overweight → Neutral
Nov-09-18	Downgrade	Guggenheim	Buy → Neutral
Oct-10-18	Initiated	Guggenheim	Buy
Jun-20-18	Initiated	BofA/Merrill	Buy	$24
Nov-15-17	Upgrade	Piper Jaffray	Neutral → Overweight

Show Previous Ratings

Feb-03-26 04:05PM	Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium 2026 (GlobeNewswire) -31.33% -7.64%
09:10AM	Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering (GlobeNewswire)
Jan-12-26 04:23AM	Sangamo Therapeutics (SGMO) Shares Stabilize Amid Recent Key Pipeline Update (Insider Monkey)
Dec-18-25 08:05AM	Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease (GlobeNewswire)
Dec-02-25 08:05AM	Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy (GlobeNewswire)
08:05AM	Loading…
Nov-21-25 08:05AM	Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease (GlobeNewswire) +9.97%
Nov-06-25 09:15AM	Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -16.29%
08:17AM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
08:01AM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 04:01PM	Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call (GlobeNewswire)
Sep-04-25 08:05AM	Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 (GlobeNewswire)
Aug-14-25 12:00PM	What Makes Sangamo (SGMO) a New Buy Stock (Zacks)
Aug-07-25 05:40PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -8.93% -5.33%
04:41PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results (GlobeNewswire)
04:05PM	Loading…
Jul-31-25 04:05PM	Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call (GlobeNewswire)
08:40AM	Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jul-03-25 09:18AM	H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data (Insider Monkey)
Jun-24-25 08:05AM	Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease (Business Wire) +18.94%
May-13-25 01:01PM	Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com) -38.40%
12:14PM	Q1 2025 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 06:26PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results (Business Wire) +6.66%
06:23PM	Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering (Business Wire)
05:55PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:53PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day (Business Wire)
May-08-25 09:15AM	Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates (Zacks) +10.67%
May-06-25 04:35PM	Sangamo Therapeutics Announces First Quarter 2025 Earnings Call (Business Wire) -15.00% +6.27%
08:30AM	Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease (Business Wire)
May-05-25 10:00AM	Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
10:01AM	Loading…
May-01-25 10:01AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-28-25 04:31PM	Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire) -5.93%
Apr-04-25 02:57PM	Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (Seeking Alpha) +5.50%
Apr-03-25 04:01PM	Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System (Business Wire)
Mar-18-25 09:00AM	Q4 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -16.23%
03:01AM	Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-17-25 05:10PM	Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-06-25 04:05PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference (Business Wire) +14.30%
Feb-06-25 08:05AM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile (Business Wire)
Jan-07-25 11:32AM	Sangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025 (Insider Monkey)
Jan-02-25 07:03AM	Sangamo Therapeutics Stock Plummets 56% After Pfizer Ends Hemophilia Treatment Partnership (Barrons.com) +10.78%
Dec-31-24 11:52AM	Top Stock Movers Now: Moderna, Verisign, Dave, and More (Investopedia) -56.41%
11:18AM	Pfizer Exit Sends Sangamo Plummeting 50%, Casting Doubt on Hemophilia Gene Therapy's Future (GuruFocus.com)
10:34AM	Sangamo Therapeutics Stock Crashes as Pfizer Ends Hemophilia Drug Pact (Investopedia)
10:23AM	SGMO Pre-Market Shares Drop 40% Over Pfizer (PFE) Deal Collapse (Insider Monkey)
09:56AM	Sangamo stock plummets 50% after Pfizer ends gene therapy deal (Yahoo Finance Video)
09:55AM	Sangamo Plunges After Pfizer Ends Pact for Hemophilia Drug (Bloomberg)
09:14AM	Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact (Benzinga)
08:30AM	Sangamos stock sinks 50% as Pfizer halts haemophilia A gene therapy partnership (Pharmaceutical Technology)
06:38AM	Sangamo stock crashes 50% after Pfizer terminates HemoA gene therapy deal (Investing.com)
Dec-30-24 04:15PM	Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizers Decision to Cease Development of Giroctocogene Fitelparvovec (Business Wire) -8.59%
02:56PM	Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-20-24 04:37AM	Astellas and Sangamo sign capsid deal for neurological diseases (Pharmaceutical Technology) +6.93%
Dec-19-24 02:30AM	Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases (Business Wire)
02:30AM	Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases (PR Newswire)
Nov-19-24 04:15PM	Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain (Business Wire)
Nov-13-24 09:49AM	Q3 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -9.96%
02:16AM	Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 05:15PM	Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:09PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results (Business Wire)
Nov-04-24 04:15PM	Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (Business Wire) -7.45% +24.14%
Oct-23-24 07:45AM	Merck acquires cancer drug startup; Elevidys ex-US sales rise (BioPharma Dive) +27.27%
Oct-22-24 08:05AM	Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 (Business Wire) +32.53%
Aug-07-24 01:24PM	Q2 2024 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -13.46%
04:32AM	Genentech and Sangamo to develop neurodegenerative disease therapies (Pharmaceutical Technology)
Aug-06-24 05:35PM	Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +28.95%
04:37PM	Sangamo: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results (Business Wire)
08:11AM	Roche licenses Sangamos technology for another shot at Alzheimers drugs (BioPharma Dive)
08:05AM	Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases (Business Wire)
Jul-30-24 04:15PM	Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (Business Wire) -23.64% +11.80%
Jul-24-24 06:55AM	Sangamo Therapeutics Reports on Pfizers Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate (Business Wire) +39.55%
May-12-24 08:28AM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 03:58PM	Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic Highlights (GuruFocus.com) +7.26%
May-09-24 08:58PM	SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:25PM	Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Sangamo: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results (Business Wire)
10:46AM	Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:05AM	Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing (Business Wire)
May-02-24 04:15PM	Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast (Business Wire) +6.48%
Apr-22-24 04:35PM	Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) (Business Wire)
Mar-22-24 08:05AM	Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering (Business Wire) -27.55%
Mar-14-24 07:23AM	Q4 2023 Sangamo Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:21AM	Sangamo: Q4 Earnings Snapshot (Associated Press Finance) -8.83%
08:05AM	Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
08:01AM	Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs (Business Wire)
Mar-12-24 06:30PM	Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast (Business Wire)
Feb-12-24 08:05AM	Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease (Business Wire) +40.15%
Feb-05-24 06:01PM	Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile (Business Wire) +13.91% -7.02%
Nov-03-23 05:03PM	Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:15AM	Sangamo to cut jobs again with planned business overhaul (BioPharma Dive) -22.14%
Nov-01-23 07:05PM	Sangamo Therapeutics Inc (SGMO) Announces Q3 2023 Financial Results and Strategic Update (GuruFocus.com) -6.25%
04:13PM	Sangamo: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results (Business Wire)
Oct-26-23 10:02AM	Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-25-23 04:15PM	Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast (Business Wire)

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.

DYN

Dyne Therapeutics Inc

SGMO

Sangamo Therapeutics Inc

Upgrade your FINVIZ experience